A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy

被引：0
|
作者：
Kenjiro Aogi
Hiroshi Sakai
Hirohisa Yoshizawa
Norikazu Masuda
Nobuyuki Katakami
Yasuhiro Yanagita
Kenichi Inoue
Masaru Kuranami
Mitsuhiro Mizutani
Noriyuki Masuda
机构：
[1] National Hospital Organization Shikoku Cancer Center,Department of Breast Oncology
[2] Saitama Cancer Center,Department of Thoracic Oncology
[3] Niigata University Medical and Dental Hospital,Bioscience Medical Research Center
[4] National Hospital Organization Osaka National Hospital,Department of Surgery
[5] Institute of Biomedical Research and Innovation,Division of Integrated Oncology
[6] Gunma Cancer Center,Department of Breast Oncology
[7] Saitama Cancer Center,Department of Breast Oncology
[8] Kitasato University School of Medicine,Department of Surgery
[9] Aichi Cancer Center Aichi Hospital,Department of Breast Surgery
[10] Kitasato University School of Medicine,Department of Respiratory Medicine
来源：
Supportive Care in Cancer | 2012年 / 20卷
关键词：
Palonosetron; 5-HT; receptor antagonist; Antiemetic; Chemotherapy-induced nausea and vomiting; Highly emetogenic chemotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1507 / 1514
页数：7
相关论文
共 50 条
  • [41] Prevention of chemotherapy-induced nausea and vomiting (CINV) over repeated chemotherapy cycles: Results of a phase 3 trial of NEPA, a fixed oral dose combination of netupitant and palonosetron
    Gralla, R. J.
    Bosnjak, S. M.
    Balser, C.
    Rizzi, G.
    Borroni, M. E.
    Rossi, G.
    Jordan, K.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S267 - S267
  • [42] Phase II Study on EANI Combined with Hydrochloride Palonosetron for Prevention of Chemotherapy-induced Nausea and Vomiting Following Highly Emetogenic Chemotherapy
    Xiao, Yang
    Liu, Jun
    Liu, Yang-Chen
    Huang, Xin-En
    Guo, Jian-Xong
    Wei, Wei
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (09) : 3951 - 3954
  • [43] Duration of Chemotherapy-Induced Nausea and Vomiting (CINV) as a Predictor of Recurrent CINV in Later Cycles
    Navari, Rudolph
    Binder, Gary
    Molasiotis, Alex
    Herrstedt, Jorn
    Roeland, Eric J.
    Ruddy, Kathryn J.
    LeBlanc, Thomas W.
    Kloth, Dwight D.
    Klute, Kelsey A.
    Papademetriou, Eros
    Schmerold, Luke
    Schwartzberg, Lee
    ONCOLOGIST, 2022, : 208 - 213
  • [44] Assessing the Benefit of NEPA (Fixed Combination of Netupitant/Palonosetron) for preventing Chemotherapy-induced Nausea and Vomiting (CINV) in patients at increased emetic risk receiving moderately emetogenic chemotherapy
    Karthaus, M.
    Christoph, D. C.
    Lux, M. P.
    Hofheinz, R. -D
    Jordan, K.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 252 - 253
  • [45] Assessing the benefit of NEPA (fixed combination of netupitant/palonosetron) for preventing chemotherapy-induced nausea and vomiting (CINV) in patients at increased emetic risk receiving moderately emetogenic chemotherapy
    Molasiotis, A.
    Aapro, M. S.
    Alonzi, A.
    Chrapava, M.
    Jordan, K.
    Roeland, E. J.
    Schwartzberg, L. S.
    Terrasanta, C.
    Olivari, S.
    Dranitsaris, G.
    ANNALS OF ONCOLOGY, 2022, 33 : 1546 - 1546
  • [46] Analysis of phase III clinical studies for palonosetron, ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV).
    Barbour, S. Y.
    Morrow, G. R.
    Ahmed, R.
    Ballinari, G.
    Thorn, M. D.
    Cox, D.
    Schwartzberg, L. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [47] A multicycle phase III study evaluating palonosetron vs ondansetron at preventing chemotherapy-induced nausea and vomiting in pediatric patients
    Kabickova, E.
    Wachtel, A.
    Basharova, E.
    Spinelli, T.
    Nicolas, P.
    Kovacs, G.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S237 - S237
  • [48] Efficacy and safety of oral palonosetron compared with IV palonosetron administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with solid tumors receiving cisplatin-based highly emetogenic chemotherapy (HEC)
    Karthaus, Meinolf
    Tibor, Csoszi
    Lorusso, Vito
    Singh-Arora, Rajender
    Filippov, Alexander
    Rizzi, Giada
    Borroni, Maria Elisa
    Rossi, Giorgia
    Grunberg, Steven M.
    SUPPORTIVE CARE IN CANCER, 2015, 23 (10) : 2917 - 2923
  • [49] Phase 3 study of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting during repeated moderately emetogenic chemotherapy (MEC) cycles.
    Aapro, Matti S.
    Karthaus, Meinolf
    Schwartzberg, Lee Steven
    Rossi, Giorgia
    Rizzi, Giada
    Borroni, Maria Elisa
    Palmas, Marco
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [50] Efficacy and safety of rolapitant in the prevention of chemotherapy-induced nausea and vomiting (CINV) in elderly patients
    Aapro, M. S.
    Arora, S.
    Powers, D.
    ANNALS OF ONCOLOGY, 2016, 27
12345